Michael Cipriano

Dec 6, 2024 | insights.citeline.com | Michael Cipriano |Bridget Silverman |Mary Jo Laffler

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDAThe latest drug development news and highlights from our FDA Performance Tracker.

Oct 21, 2024 | insights.citeline.com | Michael Cipriano

Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits? 21 Nov 2016 • By Michael CiprianoCompanies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.

Mar 6, 2024 | mcipriano-042691.medium.com | Michael Cipriano

As an investor in Newchip Accelerator via parent company ASTRALABS, I wanted to share a few thoughts on the ongoing bankruptcy proceedings, and the founder/CEO. Andrew Ryan, formerly Ryan Rafols, totally failed ASTRALABS shareholders over through mismanagement. He drove Astralabs into bankruptcy, conned small time investors, and every shareholder should be angry at him.